Explore baxter.com

This site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative.

Renal Care EMEA

Therapies

We deliver and support renal therapies across the continuum of care, including the innovative HDx.

Therapies
  • Modern PD

    Modern PD offers patients many choices. Are you ready to voice them?

  • Peritoneal Dialysis

    Peritoneal Dialysis - combined with Remote Patient Management - offers the potential to improve renal patients' clinical outcomes and increase lifestyle flexibility.

  • Hemodialysis

    Hemodialysis is the predominant therapy for end-stage kidney disease, and can be delivered through multiple therapy options.

  • HDx

    Innovative Expanded Hemodialysis (HDx) therapy is the next evolution in hemodialysis treatment.

Products

Learn more about Baxter’s key products for Renal Care – across the continuum of care.

Data & Insights

Groundbreaking research and inspirational patient stories.

  • Clinical Data

    Explore the research enabling innovative Renal Care.

  • Stories

    Patients’ journeys inspire our work and drive our commitment.

  • Resource Library

    Access resources for Baxter’s broader Renal Care portfolio.

Clinical Data

Clinical research lies at the heart of who we are. Baxter uses scientific evidence systematically, and transparently, to inform the development of new and state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Baxter. 

A Focus on Clinical Research

PD

Novel applications of remote patient management to improve outcomes in peritoneal dialysis

View resource
PD

Trends in outcomes for an automated peritoneal dialysis program with and without remote management in Columbia - Sanabria M, et al.

View resource
HDx

A Global Study Assessing Albumin Levels on Expanded Hemodialysis

View resource
HDx

Evaluation of Albumin Loss During Hemodialysis with Theranova® Medium Cut-Off (MCO) Dialyzer: Six Months Follow-Up

View resource
HDx

Current approaches to middle molecule removal: room for innovation

View resource
HDx

Cardiovascular disease in dialysis patients

View resource
HDx

New medium cut-off membrane vs online hemodiafiltration in clearance of middle molecules. Preliminary results from our centre

View resource
HDx

Comparison of high flux hemodialyzers with medium cut-off dialyzer on the removal of middle high size uremic toxins

View resource
HDx

From old uraemic toxins to new uraemic toxins: place of 'omics'

View resource
HDx

Middle cut off (MCO) dialyzers in patients with multiple myeloma - removal of light chains with HDx-therapy

View resource
HDx

Expanded haemodialysis: from operational mechanism to clinical results

View resource
HDx

Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules

View resource

Are you interested in additional information about ways in which we are transforming Renal Care through Patient-Centric Innovations?

Request information here

About Us
Baxter has been a front-runner in the treatment and management of end-stage kidney disease for over 85 years. Today, our state-of-the-art solutions for both hemodialysis and peritoneal dialysis are transforming global renal care. It’s why you can rely on us to be the type of dedicated partner who understands the challenges you face throughout the continuum of care to meet the individual needs of your patients.
 

Baxter, AK 98, AN69, Artis Physio Plus, BiCart, CWP 800, Evodial, Homechoice, Nephral ST, Novaline, Polyflux, Revaclear, Sharesource, Sharesource Adequest, SoftPac, SelectBag, Theralite and Theranova are trademarks of Baxter International Inc. or its subsidiaries.

©Copyright 2024 Baxter. All rights reserved.